
    
      Non-interventional, open-label, single group, multicentric post-marketing surveillance to
      monitor the safety and effectiveness of TYKERB® tablets administered in Korean patients
      according to the prescribing information

      TYKERB® tablets will be administered with capecitabine for HER2 overexpressing advanced or
      metastatic breast cancer treatment or with letrozole for the treatment of postmenopausal
      women with hormone receptor positive metastatic breast cancer that overexpresses the HER2 as
      described the prescribing information of TYKERB® tablets
    
  